{"id":"W3087469327","doi":"10.1016/j.clml.2020.08.022","title":"Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; AstraZeneca France; Servier; Incyte; AbbVie; Genentech; Bayer; Celgene; Bristol-Myers Squibb Canada; Gilead Sciences; Novartis; Roche","keywords":"Medicine; Idelalisib; Follicular lymphoma; Adverse effect; Oncology; PI3K/AKT/mTOR pathway; Clinical trial; Lymphoma; Targeted therapy; Internal medicine; Population; Cancer; Chronic lymphocytic leukemia; Ibrutinib; Leukemia","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001461622,0.0012229,0.004205764,0.0002964355,0.0002775764,0.0001401739,0.001860178,0.001556033,0.0000624094],"category_scores_gemma":[0.001391799,0.0006513341,0.001960519,0.002144674,0.001456092,0.0001567964,0.001106625,0.001291763,0.0001668053],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.03157977,"about_ca_system_score_gemma":0.06496993,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006641995,"about_ca_topic_score_gemma":0.0002447104,"domain_scores_codex":[0.9888944,0.001756248,0.004041745,0.001719255,0.002395051,0.001193328],"domain_scores_gemma":[0.9928737,0.001345408,0.001931586,0.002669516,0.000512431,0.0006673401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007604297,0.000781047,0.0003785248,0.004578797,0.0004300606,0.0002683122,0.0001003903,0.0000170399,0.000006820223,0.0000444883,0.003007469,0.9896266],"study_design_scores_gemma":[0.08569009,0.00367172,0.02688564,0.0228006,0.005256061,0.0006121698,0.0001586753,0.004733955,0.0001163988,0.00005615021,0.8479614,0.002057164],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2581685,0.7301617,0.00000821441,0.000809061,0.002204248,0.007236608,0.0001726196,0.0001290786,0.001109959],"genre_scores_gemma":[0.2798299,0.7144387,0.0001134234,0.0008361544,0.002833791,0.0003222676,0.000515591,0.0003910798,0.0007190621],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9875695,"threshold_uncertainty_score":0.9997402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05178835764682573,"score_gpt":0.3197734926016962,"score_spread":0.2679851349548705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}